Literature DB >> 8758258

The activity and expression of thymidine phosphorylase in human solid tumours.

Y Takebayashi1, K Yamada, K Miyadera, T Sumizawa, T Furukawa, F Kinoshita, D Aoki, H Okumura, Y Yamada, S Akiyama, T Aikou.   

Abstract

Thymidine phosphorylase (dThdPase) is identical to platelet-derived endothelial cell growth factor (PD-ECGF) and has angiogenic activity. Since dThdPase seems to have an important role in angiogenesis of tumours, we measured the activity and expression of dThdPase in various tumours and the adjacent non-neoplastic tissues. We assayed dThdPase activity by spectrophotometric means, and the expression of dThdPase was examined by immunoblotting and by immunohistochemical staining using a monoclonal antibody against dThdPase. In the oesophagus, stomach, colorectum, pancreas, and lung, dThdPase activity in carcinomas was significantly higher (P < 0.05) than that in the adjacent non-neoplastic tissues. The expression level of dThdPase detected by immunoblotting correlated well with the activity of dThdPase. In the oesophagus, stomach, colorectum, gall bladder, pancreas and lung, the proportion of dThdPase-positive tumours was significantly higher (P < 0.05 or 0.01) than that of the dThdPase-positive adjacent normal tissues. In oesophageal, gastric colorectal and lung carcinomas, the proportion of dThdPase positivity in advanced carcinomas was significantly higher (P < 0.01) than that in early carcinomas. Tumour-infiltrative macrophages or lymphocytes in the lymph node, alveolar macrophages and Kupffer cells expressed high levels of dThdPase. The results indicate that dThdPase activity and expression level in many tumours are higher than those in the adjacent non-neoplastic tissues, and that dThdPase may have an important role in the proliferation of these solid tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758258     DOI: 10.1016/0959-8049(96)00061-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  46 in total

1.  A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.

Authors:  Elizabeth Dugan; Roxanne Truax; Kellen L Meadows; Andrew B Nixon; William P Petros; Justin Favaro; Nishan H Fernando; Michael A Morse; Gerard C Blobe; Herbert I Hurwitz
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

2.  Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil.

Authors:  Agnieszka Kotlarz; Małgorzata Przybyszewska; Paweł Swoboda; Joanna Miłoszewska; Monika Anna Grygorowicz; Andrzej Kutner; Sergiusz Markowicz
Journal:  Tumour Biol       Date:  2015-10-28

3.  Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.

Authors:  Agustin A Garcia; John A Blessing; Kathleen M Darcy; Heinz Josef Lenz; Wu Zhang; Ed Hannigan; David H Moore
Journal:  Gynecol Oncol       Date:  2006-10-17       Impact factor: 5.482

4.  Response of neoplastic meningitis from solid tumors to oral capecitabine.

Authors:  Pierre Giglio; Ivo W Tremont-Lukats; Morris D Groves
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

5.  Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.

Authors:  A Jimeno; C Grávalos; P Escudero; I Sevilla; M E Vega-Villegas; V Alonso; I Juez; R García-Carbonero; H Bovio; R Colomer; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

6.  Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.

Authors:  Judah Friedman; Rodney L Dunn; David Wood; Ulka Vaishampayan; Angela Wu; Deborah Bradley; James Montie; Fazlul H Sarkar; Rajal B Shah; Maha Hussain
Journal:  J Urol       Date:  2008-01-22       Impact factor: 7.450

7.  Localization of thymidine phosphorylase in advanced gastric and colorectal cancer.

Authors:  Michiya Kobayashi; Ken Okamoto; Toyokazu Akimori; Naoshige Tochika; Tadashi Yoshimoto; Takehiro Okabayashi; Takeki Sugimoto; Keijiro Araki
Journal:  J Mol Histol       Date:  2004-01       Impact factor: 2.611

8.  Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.

Authors:  Yong-Sheng Xiao; Zhao-You Tang; Jia Fan; Jian Zhou; Zhi-Quan Wu; Qi-Man Sun; Qiong Xue; Yan Zhao; Yin-Kun Liu; Sheng-Long Ye
Journal:  J Cancer Res Clin Oncol       Date:  2004-04-08       Impact factor: 4.553

9.  Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.

Authors:  Ulka N Vaishampayan; Shanthi Marur; Lance K Heilbrun; Michael L Cher; Brenda Dickow; Daryn W Smith; Samir A Al Hasan; James Eliason
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

Review 10.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.